The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers
Talmadge, J.E.; Herberman, R.B.
Cancer Treatment Reports 70(1): 171-182
1986
ISSN/ISBN: 0361-5960 PMID: 3510733 Document Number: 270807
Document emailed within 1 workday
Related Documents
Ackermann, R. 1988: Biological response modifiers in renal cancer Progress in Clinical and Biological Research 269: 313-328Ishihara, K. 1989: On the behalf of the Japanese Society of Biological Response Modifiers Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(4 Pt 2-1): 906-911
Scheinberg, M.A. 1988: Clinical trials with biological response modifiers in rheumatic diseases Journal of Rheumatology 15(7): 1056-1057
Kirkpatrick, C.H. 1989: Biological response modifiers. Interferons, interleukins, and transfer factor Annals of Allergy 62(3): 170-176
Okawa, T.; Goto, M.; Kita, M. 1987: Radiotherapy combined with BRM (biological response modifiers) in the treatment of cancer Gan no Rinsho. Japan Journal of Cancer Clinics 33(10): 1253-1256
Zlotta, A.R.; Schulman, C.C. 2000: Biological response modifiers for the treatment of superficial bladder tumors European Urology 37(Suppl): 10-15
Saito, A. 2001: A putative immunotherapy with biological response modifiers (BRM) against intractable pulmonary tuberculosis Kekkaku: 76(12): 741-747
Muss, H.B. 1988: The role of biological response modifiers in metastatic renal cell carcinoma Seminars in Oncology 15(5 Suppl 5: 30-34
Irwin, M.M. 1987: Patients receiving biological response modifiers: overview of nursing care Oncology Nursing Forum 14(6 Suppl): 32-37
Borden, E.C.; Hawkins, M.J. 1986: Biologic response modifiers as adjuncts to other therapeutic modalities Seminars in Oncology 13(2): 144-152
Koga, H.; Miyazaki, Y.; Kohno, S.; Hara, K. 1994: A drug delivery system and biological response modifiers for the treatment of mycobacterial infection Kekkaku: 69(2): 113-118
Bergmann, L. 1989: Malignant melanoma--prognosis and actual treatment strategies with chemotherapy and biological response modifiers European Journal of Cancer and Clinical Oncology 25(Suppl 3): S31-S36
Rivero Puente, A.; Burusco, M.J.; Idoate, I.; Fernández-Calvo, J.L.; García Merlo, S. 1977: Typhoid fever: clinico-biological evaluation and therapeutic response in 90 patients admitted to an internal medicine service Revista Clinica Espanola 147(2): 175-178
Talmadge, J.E.; Black, P.L.; Tribble, H.; Pennington, R.; Bowersox, O.; Schneider, M.; Phillips, H. 1987: Preclinical approaches to the treatment of metastatic disease: therapeutic properties of rH TNF, rM IFN-gamma, and rH IL-2 Drugs under Experimental and Clinical Research 13(6): 327-337
Nio, Y.; Zighelboim, J.; Berek, J.S.; Bonavida, B. 1990: Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers Anticancer Research 10(2a): 441-446
Sodhi, A.; Pai, K. 1992: Studies on the release of interleukin-1 (IL-1), tumor necrosis factor (TNF) and lysozyme from human non-adherent mononuclear cells (nMNC) in vitro after treatment with cisplatin and other biological response modifiers Neoplasma 39(4): 211-217
Baban, B.; Liu, J.Y.; Tay, F.R.; Pashley, D.H. 2012: Use of a new, simple, laboratory method for screening the antimicrobial and antiviral properties of hand sanitizers American Journal of Dentistry 25(6): 327-331
Blahoutová, V.; Zajícová, A.; Wilczek, H.; Holán, V. 2003: Opioids and their immunomodulatory properties Casopis Lekaru Ceskych 142(4): 244-247
Sengupta, M.; Sengupta, O. 1995: Correlation of biological activity (therapeutic and toxic) with solvochromic properties of metronidazole, emetine hydrochloride and diloxanide furoate Indian Journal of Biochemistry and Biophysics 32(5): 302-307
Gorbunova, M.L.; Lobanova, E.I.; Drozd, T.E.; Turliun, S.A.; Maganchuk, V.P. 1989: The effect of Aerococcus viridans--the basis of the new therapeutic-prophylactic preparation M-bacterin--on the biological properties of Staphylococcus aureus Mikrobiolohichnyi Zhurnal 51(5): 77-81